GSK's Blenrep shows strong survival benefit in myeloma study
GSK reported positive results from its phase three ‘DREAMM-7’ trial on Thursday, highlighting a significant overall survival ...
The Pharma Letter8h
Blenrep results ‘transformative’, GSK says
UK drugmaker GSK might be trading lower following Thursday’s nomination of vaccine sceptic Robert F Kennedy Jr as the USA’s ...
GSK reports positive outcomes from Phase III multiple myeloma treatment trial
GSK has announced positive headline interim analysis outcomes from a Phase III trial, which is evaluating Blenrep (belantamab ...
EMA’s CHMP recommends Sanofi’s Sarclisa approval for multiple myeloma
Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Sanofi’s Sarclisa combined with Velcade ...
PipelineReview.com13h
Blenrep shows overall survival benefit in head-to-head DREAMM-7 phase III trial for relapsed/refractory multiple myeloma
LONDON, UK I 14, 2024 I GSK plc (LSE/NYSE: GSK) today announced positive headline results from a planned interim analysis of the DREAMM-7 ...
Frontiers15h
Understanding Adverse Effect in Myeloma Patients treated with T Cell Redirecting Immunotherapies
Multiple Myeloma, a cancer of the plasma cells in the bone marrow, is the third most common blood cancer in Europe. Despite recent advanced in treatment that has increased survival, it is still an ...
Medpage Today on MSN17h
Big Comeback for Myeloma Drug; DIY Cancer Therapy; Gut Clues to Bladder Cancer
GSK announced that belantamab mafodotin (Blenrep) plus bortezomib (Velcade) and dexamethasone improved overall survival in ...
Sky News Australia22h
Ernst & Young fires dozens of staffers for taking multiple online trainings at a time - but employees say company ‘encouraged’ this
EY did not return a request for comment. Several of the fired employees said they did not think they were breaking company policy by attending multiple trainings at once. The training courses ...